Clinical aspects of the applicability of biomarkers of acute kidney injury in ischemia-reperfusion in operative urology

The development of acute kidney injury during surgical renal-preserving interventions characterizes the nature of the clinical course and prognosis for the development of chronic kidney disease. The use of standard indicators of disease progression (serum creatinine and urea nitrogen) in clinical practice can lead to unfavorable outcomes of acute kidney injury due to their low sensitivity and high specificity against the background of damage to more than 50% of the renal parenchyma). Other biomarkers of acute kidney injury (cystatin C, IL-18, KIM-1, NGAL, L-FABP, NAG and others) are superior to creatinine in sensitivity and specificity, but require additional research to identify the most optimal ones for clinical practice.